Long term and delayed effects of psychedelics in preclinical models
Transpharmation has published the results of their recent trailblazing study - long term and delayed effects of psychedelics in preclinical models - in a newsletter distributed to their network of subscribers. Research over the last few years has shown that, in addition to ketamine, psilocybin is a substance that raises great expectations. We are excited to confirm translation relevance of this in vivo model in preclinical studies, showing that Chronic Social Defeat is a valuable research tool with the potential to identify new, personalised avenues for depression therapy, including novel compounds based on psilocybin derivatives.
Our most recent data clearly indicates:
- Phenotype division in the mice population (51% susceptible and 49% resilient to stress)
- Stability of the susceptible phenotype in the C57BL/6J mice over prolong period of time
- Acute (24hr) and long lasting (7 days) antidepressant efficacy of ketamine and two doses of psilocybin after just a single administration.
Read more about it here: Long term and delayed effects of psychedelics and preclinical models or contact us to discuss the study in more detail: Contact us
At Transpharmation, we carry out sponsored preclinical translational in vivo pharmacology research into cannabidiol (CBD), ketamine, psilocybin, DMT, LSD and other psychedelics, for the treatment of neuropsychiatric disorders, providing the necessary data to propel compounds into the clinic.